相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
A. I. Phipps et al.
BRITISH JOURNAL OF CANCER (2013)
Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer
Sakarias Wangefjord et al.
DIAGNOSTIC PATHOLOGY (2013)
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer
David Capper et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer
J. Eberhard et al.
BRITISH JOURNAL OF CANCER (2012)
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2012)
Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer
Bjorn Nodin et al.
DIAGNOSTIC PATHOLOGY (2012)
BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis
Matthew F. Kalady et al.
DISEASES OF THE COLON & RECTUM (2012)
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer
Teppei Morikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
Gholamreza Safaee Ardekani et al.
PLOS ONE (2012)
Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
Catherine E. Bond et al.
PLOS ONE (2012)
Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study
Jenny Brandstedt et al.
BIOLOGY OF SEX DIFFERENCES (2012)
Modifying effect of gender on the prognostic value of clinicopathological factors and Ki67 expression in melanoma: a population-based cohort study
Marie Fridberg et al.
BIOLOGY OF SEX DIFFERENCES (2012)
Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
A. Larsson et al.
BRITISH JOURNAL OF CANCER (2011)
Association of CTNNB1 (β-Catenin) Alterations, Body Mass Index, and Physical Activity With Survival in Patients With Colorectal Cancer
Teppei Morikawa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study
Sakarias Wangefjord et al.
Biology of Sex Differences (2011)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer
Garrett M. Nash et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
Inti Zlobec et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2009)
Short term outcome after emergency and elective surgery for colon cancer
O. H. Sjo et al.
COLORECTAL DISEASE (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
Richard Gray et al.
LANCET (2007)
Correlation of β-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer
Takako Kawasaki et al.
NEOPLASIA (2007)
Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP
Shuji Ogino et al.
MODERN PATHOLOGY (2007)
Down-regulation of p21 (CDKNIA/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer
S. Ogino et al.
JOURNAL OF PATHOLOGY (2006)
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status
Wei Qi Li et al.
MOLECULAR CANCER (2006)
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component
S Ogino et al.
MODERN PATHOLOGY (2006)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan et al.
ANNALS OF ONCOLOGY (2002)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
分享论文
